NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 2 hours 22 min ago

Notice to Extend PAR-15-332, Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01)

Wed, 2017-10-04 02:06
Notice NOT-CA-17-091 from the NIH Guide for Grants and Contracts

Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed)

Tue, 2017-10-03 13:20
Funding Opportunity PAR-18-303 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.

NIH SIREN Neurologic Clinical Trials (U01 Clinical Trial Required)

Tue, 2017-10-03 12:56
Funding Opportunity PAR-18-304 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols.

Notice of NIAAA's Participation in PAR-17-070 "Innovative Program to Enhance Research Training (IPERT) (R25)

Tue, 2017-10-03 12:44
Notice NOT-AA-17-012 from the NIH Guide for Grants and Contracts

Application and Report Submission Flexibilities Available to Institutions Impacted by Hurricane Maria

Tue, 2017-10-03 09:26
Notice NOT-OD-18-002 from the NIH Guide for Grants and Contracts

NIH Operates Under a Continuing Resolution Through December 8, 2017

Mon, 2017-10-02 09:53
Notice NOT-OD-17-124 from the NIH Guide for Grants and Contracts

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)

Fri, 2017-09-29 02:33
Funding Opportunity PAR-17-496 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities. For the purposes of this FOA, the term 'Native Americans' includes the following populations: Alaska Native, American Indian, and Native Hawaiian. The term 'Native Hawaiian' means any individual whose ancestors were natives, prior to 1778, belonging to the area that now comprises the State of Hawaii. Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life.

Research to Improve Native American Health (R21 Clinical Trial Optional)

Fri, 2017-09-29 02:32
Funding Opportunity PAR-17-464 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities. For the purposes of this FOA, the term 'Native Americans' includes the following populations: Alaska Native, American Indian, and Native Hawaiian. The term 'Native Hawaiian' means any individual whose ancestors were natives, prior to 1778, belonging to the area that now comprises the State of Hawaii. Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life.

Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional)

Fri, 2017-09-29 02:06
Funding Opportunity PA-17-495 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

NIMHD Loan Repayment Program Technical Assistance Webinar

Thu, 2017-09-28 12:40
Notice NOT-MD-17-003 from the NIH Guide for Grants and Contracts

Notice of Interest to Highlight Expansion of Research Topics for the HIV/AIDS Vaccine Scholars Program (K01)

Thu, 2017-09-28 12:26
Notice NOT-OD-17-116 from the NIH Guide for Grants and Contracts

NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00)

Thu, 2017-09-28 12:19
Funding Opportunity RFA-NS-18-007 from the NIH Guide for Grants and Contracts. The purpose of the NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award is to support a defined pathway across career stages for outstanding graduate students who are from backgrounds that are nationally underrepresented in neuroscience research. This two-phase award will facilitate completion of the doctoral dissertation and transition of talented graduate students to strong neuroscience research postdoctoral positions, and will provide career development opportunities relevant to their long-term career goal of becoming independent neuroscience researchers.

NCI Outstanding Investigator Award (R35)

Thu, 2017-09-28 11:58
Funding Opportunity PAR-17-494 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

Pages